Metabolic modulation: A new therapeutic target in treatment of heart failure

Chandrasekar Palaniswamy, William Michael Mellana, Dhana R. Selvaraj, Diwakar Mohan

Research output: Contribution to journalArticle

Abstract

Treatment of heart failure involves management of risk factors and control of symptoms. Traditional management of heart failure involves the use of angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, diuretics, aldosterone antagonists, and digitalis. Metabolic modulators are a newer class of drugs that benefit these patients by modulating cardiac metabolism without altering hemodynamics. They have the potential to relieve symptoms in patients with refractory heart failure who are already on optimal medical therapy. These drugs increase glucose metabolism at the expense of free fatty acid metabolism, thereby enhancing efficient use of oxygen. This review discusses the role of 4 metabolic modulators drugs that could potentially be used for heart failure therapy: trimetazidine, ranolazine, perhexiline, and etomoxir.

Original languageEnglish (US)
JournalAmerican Journal of Therapeutics
Volume18
Issue number6
DOIs
StatePublished - Nov 2011

Fingerprint

Treatment Failure
Heart Failure
Perhexiline
Trimetazidine
Pharmaceutical Preparations
Mineralocorticoid Receptor Antagonists
Digitalis
Angiotensin Receptor Antagonists
Therapeutics
Angiotensin-Converting Enzyme Inhibitors
Nonesterified Fatty Acids
Diuretics
Hemodynamics
Oxygen
Glucose

Keywords

  • etomoxir
  • metabolic modulators
  • perhexiline
  • ranolazine
  • trimetazidine

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Metabolic modulation : A new therapeutic target in treatment of heart failure. / Palaniswamy, Chandrasekar; Mellana, William Michael; Selvaraj, Dhana R.; Mohan, Diwakar.

In: American Journal of Therapeutics, Vol. 18, No. 6, 11.2011.

Research output: Contribution to journalArticle

Palaniswamy, Chandrasekar ; Mellana, William Michael ; Selvaraj, Dhana R. ; Mohan, Diwakar. / Metabolic modulation : A new therapeutic target in treatment of heart failure. In: American Journal of Therapeutics. 2011 ; Vol. 18, No. 6.
@article{47db2260d51f4355bec1be60bd7ff57f,
title = "Metabolic modulation: A new therapeutic target in treatment of heart failure",
abstract = "Treatment of heart failure involves management of risk factors and control of symptoms. Traditional management of heart failure involves the use of angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, diuretics, aldosterone antagonists, and digitalis. Metabolic modulators are a newer class of drugs that benefit these patients by modulating cardiac metabolism without altering hemodynamics. They have the potential to relieve symptoms in patients with refractory heart failure who are already on optimal medical therapy. These drugs increase glucose metabolism at the expense of free fatty acid metabolism, thereby enhancing efficient use of oxygen. This review discusses the role of 4 metabolic modulators drugs that could potentially be used for heart failure therapy: trimetazidine, ranolazine, perhexiline, and etomoxir.",
keywords = "etomoxir, metabolic modulators, perhexiline, ranolazine, trimetazidine",
author = "Chandrasekar Palaniswamy and Mellana, {William Michael} and Selvaraj, {Dhana R.} and Diwakar Mohan",
year = "2011",
month = "11",
doi = "10.1097/MJT.0b013e3181d70453",
language = "English (US)",
volume = "18",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Metabolic modulation

T2 - A new therapeutic target in treatment of heart failure

AU - Palaniswamy, Chandrasekar

AU - Mellana, William Michael

AU - Selvaraj, Dhana R.

AU - Mohan, Diwakar

PY - 2011/11

Y1 - 2011/11

N2 - Treatment of heart failure involves management of risk factors and control of symptoms. Traditional management of heart failure involves the use of angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, diuretics, aldosterone antagonists, and digitalis. Metabolic modulators are a newer class of drugs that benefit these patients by modulating cardiac metabolism without altering hemodynamics. They have the potential to relieve symptoms in patients with refractory heart failure who are already on optimal medical therapy. These drugs increase glucose metabolism at the expense of free fatty acid metabolism, thereby enhancing efficient use of oxygen. This review discusses the role of 4 metabolic modulators drugs that could potentially be used for heart failure therapy: trimetazidine, ranolazine, perhexiline, and etomoxir.

AB - Treatment of heart failure involves management of risk factors and control of symptoms. Traditional management of heart failure involves the use of angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, diuretics, aldosterone antagonists, and digitalis. Metabolic modulators are a newer class of drugs that benefit these patients by modulating cardiac metabolism without altering hemodynamics. They have the potential to relieve symptoms in patients with refractory heart failure who are already on optimal medical therapy. These drugs increase glucose metabolism at the expense of free fatty acid metabolism, thereby enhancing efficient use of oxygen. This review discusses the role of 4 metabolic modulators drugs that could potentially be used for heart failure therapy: trimetazidine, ranolazine, perhexiline, and etomoxir.

KW - etomoxir

KW - metabolic modulators

KW - perhexiline

KW - ranolazine

KW - trimetazidine

UR - http://www.scopus.com/inward/record.url?scp=81755184785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81755184785&partnerID=8YFLogxK

U2 - 10.1097/MJT.0b013e3181d70453

DO - 10.1097/MJT.0b013e3181d70453

M3 - Article

C2 - 20393344

AN - SCOPUS:81755184785

VL - 18

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 6

ER -